Marino Garcia is the CEO of Dianthus Therapeutics, appointed in September 2023, following a significant transition in company leadership. He has a solid foundation in business with an M.B.A from Ivey Business School and a Bachelor of Commerce from Concordia...

Marino Garcia is the CEO of Dianthus Therapeutics, appointed in September 2023, following a significant transition in company leadership. He has a solid foundation in business with an M.B.A from Ivey Business School and a Bachelor of Commerce from Concordia University. His career spans various roles within the biopharmaceutical industry, with notable positions at Zealand Pharma, Synergy Pharmaceuticals, and Aptalis Pharma. Garcia’s strategic vision focuses on drug development and clinical trial preparedness, which aligns with Dianthus's current goals. In 2023, his compensation included a base salary of $174,863 and a bonus of $321,159, reflecting his performance-driven approach. Additionally, he recently became a board member and will serve until the company’s 2025 annual meeting. His leadership comes at a time when the company aims to innovate significantly in its clinical pipeline. Garcia’s diverse experience and expertise in business development bring a solid perspective as Dianthus navigates its goals.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Dianthus Therapeutics CEOs

D

Marino Garcia

CEO of Dianthus Therapeutics

Education

M.B.A. from the Ivey Business School at Western University and Bachelor of Commerce from Concordia University

Field of Expertise

Business & Management - Business Development

Sector of Economy

Healthcare

Born

January 1, 1966 - 59 years ago

CEO of Dianthus Therapeutics for

1 year 8 months (Sep 2023 - Present)

Previous Experience

Senior Vice President, Corporate and Business Development at Zealand Pharma A/S

Rivals

Competitors/colleagues of Marino Garcia

Holdings

See how much did Marino Garcia make over time.

Marino Garcia holds a stake in Dianthus Therapeutics, where he began as CEO in September 2023. Before this, he was involved in various leadership roles in the biopharmaceutical sector, leading to a wealth of experience. His holdings reflect his commitment...

Marino Garcia holds a stake in Dianthus Therapeutics, where he began as CEO in September 2023. Before this, he was involved in various leadership roles in the biopharmaceutical sector, leading to a wealth of experience. His holdings reflect his commitment to the company, but the significant changes in leadership and compensation metrics highlight a strategic shift at Dianthus. His previous positions, at Zealand Pharma and Synergy Pharmaceuticals, showcase his ability to drive growth. With a concentrated focus, Garcia’s net worth appears tied mainly to his role at Dianthus, emphasizing his investment in the firm’s future and success.

Loading...

Insider Trading

See recent insider trades of Marino Garcia.

No insider trades found for this CEO.

Compensation History

See how much did Marino Garcia make over time.

In 2023, Marino Garcia's total compensation as CEO of Dianthus Therapeutics amounted to $496,022. This includes a base salary of $174,863 and a performance-based bonus of $321,159, which demonstrates his focus on achieving company milestones in drug development. His compensation structure is designed to align closely with the company’s performance, aiming to motivate leadership to meet critical business objectives. Garcia's pay reflects his accountability for the future of Dianthus, especially following the company's recent merger and subsequent changes in strategy. The company adopts a philosophy of tying executive pay directly to performance metrics, which in Garcia's case means achieving success in clinical trials and pipeline development, two key areas of focus for his leadership team.

Year

2023

Total Compensation

$496.02K

Salary

$174.86K

Board Justification

The compensation philosophy focuses on aligning executive compensation with company performance, peer benchmarking, and retention strategies, aiming to motivate executives to achieve short- and long-term results in the best interests of stockholders.

Bonus

$321.16K

Board Justification

The bonus is based on the annual cash incentive payouts earned for performance in 2023, which are expected to be paid in February 2024. The annual incentive program was based on achievement of corporate performance goals related to clinical trial readiness and pipeline development, with payouts approved at 115% of target.

Other

$0.00

Board Justification

No other compensation was reported for 2023.

Restricted Stock

$0.00(0 common stock)

Board Justification

No stock was reported as vested in 2023.

Performance Metrics

The performance metrics for determining compensation in 2023 included execution towards organizational readiness for clinical trials and pipeline development.

Other Dianthus Therapeutics CEOs

Here are other CEOs of Dianthus Therapeutics

Jason Gardner

Founder and Ex-CEO of Dianthus Therapeutics

January 2022 - February 2023